Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

2 Mar 2023

Abstract excerpt

Objective: The choice of chemotherapeutic regimen for triple-negative breast cancer (TNBC) remains controversial. Homologous recombination deficiency (HRD) has attracted increasing attention in informing chemotherapy treatment. This study was aimed at investigating the feasibility of HRD as a clinically actionable biomarker for platinum-containing and platinum-free therapy. Methods: Chinese patients with TNBC who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36861447
DOI: 10.20892/j.issn.2095-3941.2022.0525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerPMID 36861447Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.Semantic proximity Read ↗

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Semantic proximity Read ↗

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencingSemantic proximity Read ↗

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialSemantic proximity Read ↗

qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.